Vanguards of Healthcare by Bloomberg Intelligence

BioLink CEO Rich Yang details Shine sensor tech, OTC clearance, and insulin dosing roadmap

41 min Listen to the original Episode page
Medical DevicesDiabetesCGMBiotechDigital HealthRegulatoryManufacturingWearables

Summary

BioLink CEO Rich Yang explains that the Shine sensor uses a 2mm silicon wafer with seven micro-probes to access the papillary dermis, eliminating hypodermic needles. He highlights the company's recent FDA OTC clearance and strategy to target the 90-95% of Type 2 diabetics not on insulin. Yang discusses using real-time LED feedback for cognitive restructuring and manufacturing advantages via semiconductor foundries. The company plans a pivotal trial for insulin dosing claims, targeting FDA submission next year, while developing a second-generation device with doubled electrode density.

Key takeaways

  1. 1
    BioLink uses redundancy with multiple independent channels of glucose information to ensure repeatable accuracy, aiming for industry-leading accuracy as manufacturing processes mature.

    Unidentified speaker (speaker_1) · 19:18

Episode sections

  1. 0:20 – 2:37

    Introduction and Technology Overview

    Matt Henriksson introduces Rich Yang, CEO of BioLink, who explains that BioLink's Shine sensor uses a 2mm x 2mm silicon wafer with seven micro-probes to access the papillary dermis, eliminating the need for hypodermic needles or introducer filaments.

  2. 2:37 – 4:28

    Manufacturing Moat and Silicon Durability

    Yang describes the difficulty of miniaturizing electrochemical sensors, noting that silicon is harder than titanium and steel at the nanoscale. He highlights the ability to leverage semiconductor foundries for mass production, making the technology cost-effective and robust compared to fragile microneedles.

  3. 4:28 – 6:44

    Targeting Type 2 Diabetes and Low Adoption

    The discussion shifts to the Type 2 diabetes market, which represents 90-95% of diabetics and has low CGM adoption. Yang identifies barriers such as introducer needles and alarm fatigue, proposing a solution that removes needles and provides context through activity and sleep data.

  4. 6:44 – 13:35

    LED Nudges and Cognitive Restructuring

    Yang explains the use of an LED light on the wearable to provide real-time feedback without draining the battery via a phone app. This 'simple nudge' aims to drive cognitive restructuring, helping users learn from immediate feedback (e.g., seeing a yellow light after eating cheesecake) rather than relying on retrospective data.

  5. 13:35 – 15:39

    Sensor Adhesion and Signal Reliability

    Addressing how the tiny sensor stays on the skin, Yang notes that secure tape and protruding probes ensure contact. He emphasizes that individually addressable probes allow the system to detect if a probe is dislodged, as the signal would go to zero, ensuring reliability.

  6. 15:39 – 20:12

    Accuracy, Redundancy, and Insulin Claims

    Yang discusses the trade-off between accuracy and reliability, citing built-in redundancy with multiple independent channels. He states that while current products target non-insulin users, BioLink is working on an insulin dosing claim to be submitted to the FDA next year.

  7. 20:12 – 27:00

    Manufacturing Scale and AI Integration

    Yang details the manufacturing process, which uses electroplating to grow membranes on microsensors. He explains the progression from manual optimization to semi-automation and full automation, leveraging AI to monitor sensor health in real-time and filter out outliers during production.

  8. 27:00 – 34:28

    OTC Clearance and Reimbursement Strategy

    Yang expresses gratitude for the recent FDA OTC clearance, which enables e-commerce and DTC channels. He outlines a strategy to generate real-world evidence over the next 18 months to secure reimbursement pathways, aiming to reduce healthcare costs by delaying disease progression in Type 2 patients.

  9. 34:28 – 36:03

    Clinical Trial Requirements for Insulin Dosing Claims

    Speaker_1 explains that demonstrating insulin dosing claims requires a rigorous pivotal trial, distinct from real-world data collection. The trial for Biolinq Shine included two-thirds of subjects with type 1 diabetes and 90% on insulin to ensure accuracy across glucose ranges, with 50% classified as obese. A new large pivotal trial including pediatrics is planned for insulin dosing claims, with an FDA submission intended for next year.

  10. 36:03 – 38:23

    Second-Generation Device Specifications and Roadmap

    The second-generation flagship product is 40% smaller than the first generation and designed for scale to achieve free cash flow. It will support expanded claims including prescription for type 2 diabetes, over-the-counter use, and insulin dosing on a single hardware platform. The underlying chip technology has doubled its electrode density from seven to fifteen in the same footprint.

  11. 38:23 – 40:58

    Vision for Lowering Barriers to Metabolic Health

    Speaker_1 emphasizes lowering barriers to glucose and metabolism monitoring, viewing glucose as a vital sign. The goal is to make devices easy to use, such as removing introducer needles or applicators, and potentially adding LED features like icons or trends. The objective is to encourage annual use for everyone to improve metabolic health and longevity.

Claims worth verifying

BioLink is a privately held medical device company developing biowearables, including Shine, the first glucose sensor with no hypodermic needles for insertion.

Unidentified speaker (speaker_0) ·0:20

How to verify: Company website or press releases; SEC EDGAR for any private placement filings if available. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

The Shine sensor uses a 2mm by 2mm silicon die with seven micro-probes to access the papillary dermis.

Unidentified speaker (speaker_1) ·1:24

How to verify: FDA 510(k) summary for BioLink Shine; company technical documentation. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Silicon is harder than titanium and steel at the nanoscale.

Unidentified speaker (speaker_1) ·3:11

How to verify: Materials science literature or nanotechnology textbooks regarding hardness properties of silicon vs. metals at the nanoscale. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Type 2 diabetes patients not on insulin represent 90-95% of people with diabetes.

Unidentified speaker (speaker_1) ·4:39

How to verify: CDC National Diabetes Statistics Report or American Diabetes Association epidemiological data. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

BioLink's microsensors are the first semiconductor microarray cleared by the FDA for glucose monitoring.

Unidentified speaker (speaker_1) ·2:04

How to verify: FDA 510(k) clearance database search for BioLink Shine. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

BioLink intends to submit an insulin dosing claim to the FDA next year (2027).

Unidentified speaker (speaker_1) ·17:15

How to verify: Future FDA submissions or press releases from BioLink in 2026. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

BioLink uses electrodeposition to grow membranes on the tips of microsensors.

Unidentified speaker (speaker_1) ·21:44

How to verify: Patent filings by BioLink or technical white papers describing the manufacturing process. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

BioLink received FDA over-the-counter (OTC) clearance in September 2026.

Unidentified speaker (speaker_1) ·27:00

How to verify: FDA press releases or 510(k) database updates for September 2026. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

BioLink plans to generate real-world evidence over the next 18 months to seek reimbursement pathways.

Unidentified speaker (speaker_1) ·29:05

How to verify: Company investor presentations or press releases detailing clinical study timelines. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

JDRF funded outcome studies that increased access for people with diabetes on insulin for sensors.

Unidentified speaker (speaker_1) ·30:58

How to verify: JDRF published reports or press releases regarding sensor access studies. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Real-world data is insufficient for insulin dosing claims; an aggressive pivotal trial is required.

Unidentified speaker (speaker_1) ·34:47

How to verify: Review Biolinq's FDA submission documents or clinical trial registries (e.g., ClinicalTrials.gov) for the insulin dosing pivotal trial design and requirements. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

90% of subjects in the Shine pivotal trial were on insulin.

Unidentified speaker (speaker_1) ·35:07

How to verify: Verify against the clinical study report for Biolinq Shine or FDA approval summaries. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

50% of subjects in the Shine pivotal trial were classified as obese.

Unidentified speaker (speaker_1) ·35:17

How to verify: Cross-reference with the demographic data in the Biolinq Shine pivotal trial publication or FDA submission. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

The insulin dosing pivotal trial must include pediatric subjects.

Unidentified speaker (speaker_1) ·35:24

How to verify: Review the protocol for the new insulin dosing trial filed with the FDA or ClinicalTrials.gov. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Biolinq intends to submit the insulin dosing claim to the FDA next year.

Unidentified speaker (speaker_1) ·35:35

How to verify: Monitor FDA submission timelines or Biolinq press releases for the expected submission date. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

The second-generation device will support RX for type 2s, OTC, and insulin dosing claims on the same hardware.

Unidentified speaker (speaker_1) ·36:23

How to verify: Review Biolinq's product roadmap announcements or FDA clearance letters for the new device. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

The chip density has doubled from seven to fifteen electrodes in the same footprint.

Unidentified speaker (speaker_1) ·37:03

How to verify: Examine Biolinq's technical white papers, patent filings, or product specifications for the microsensor array details. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

Do your own research

  • Verify BioLink's FDA OTC clearance status and specific indications for use via the FDA database.
  • Review the design and results of the Biolinq Shine pivotal trial, specifically the 90% insulin-using subject cohort.
  • Check for any disclosed conflicts of interest or equity holdings by Bloomberg Intelligence or the speakers in BioLink.
  • Analyze the competitive landscape of needle-free CGM sensors, including patents held by BioLink and competitors.
  • Assess the timeline and regulatory pathway for the planned pediatric insulin dosing trial.
  • Research the reimbursement landscape for OTC CGMs and potential payer policies for Type 2 diabetes management.
  • Evaluate the manufacturing scalability claims by reviewing BioLink's partnerships with semiconductor foundries.
Full transcriptexpand
0:20
Unidentified speaker (speaker_0): Welcome to another exciting episode of the Vanguards of Healthcare series. My name is Matt Henriksen, Henrickson, the medical technology analyst. at Bloomberg Intelligence, which is the in-house equity research platform of Bloomberg LP. We are pleased to have back with us today Rich Yang, CEO of BioLink. BioLink is a privately held medical device company that is developing
0:40
Unidentified speaker (speaker_0): biowearables, including Shine, the first glucose center with no hypodermic needles for insertion. Rich, thanks for joining us again today.
0:49
Unidentified speaker (speaker_1): It's great to be back. Thanks, Matt. And to see you.
0:51
Unidentified speaker (speaker_0): Great to see you too.
0:52
Unidentified speaker (UNKNOWN): Looking
0:53
Unidentified speaker (speaker_1): good.
0:53
Unidentified speaker (speaker_0): Thank you. Thank you. Um, trying to stay healthy, yeah. I think uh, you know, we'll probably dive deep into the CGMs, but I've used some of those uh over-the-counter ones before to kind of keep the glucose levels uh steady. But enough about me. Let's jump right into BioLink. And you know, we were back on here about a year ago. We were talking about some exciting trends. You had just received the initial
1:13
Unidentified speaker (speaker_0): FDA approval. But, you know, when I talk about first glucose sensor with no hypodermic needle, what exactly is that for listeners who didn't hear last year's episode?
1:24
Unidentified speaker (speaker_1): Yes, we use microsensors. Okay. So which means um we we have a substrate um etched out of a silicon wafer, and we etch tiny little microsensors in a very small chip. It's about a two millimeter by two millimeter die. And we have seven micro probes
1:44
Unidentified speaker (speaker_1): that come off of this silicon wafer. And that allows us to have a very robust substrate for electrochemistry, and that allows us to access the most metabolically active tissue in the body, which is the papillary dermis. It sits right on top of the capillary bed. So because we don't have a filament that needs to reside in the subcutaneous space,
2:04
Unidentified speaker (speaker_1): there's no introducer needle that has to punch in a filament for biosensing. So the microsensors are the first semiconductor microarray cleared by the FTA for glucose monitoring.
2:18
Unidentified speaker (speaker_0): Okay. So what was the the the specific technology for that? Because that sounds simple. It sounds like a clear, obvious, okay, if I do scrolls,
2:26
Unidentified speaker (UNKNOWN): I'm going to go
2:26
Unidentified speaker (speaker_0): ahead just go right below the skin where most of the data is gonna be, I should go for there first. But why what what's the moat or what's the hurdle for other companies to have been able to
2:36
Unidentified speaker (UNKNOWN): try
2:36
Unidentified speaker (speaker_0): to do that?
2:37
Unidentified speaker (speaker_1): It's incredibly difficult. Perhaps I would say one of the moonshots, at least in in the diabetes space. And miniaturization Miniaturiz of electrochemical sensors has eluded industry because it's incredibly hard to miniaturize
2:51
Unidentified speaker (speaker_1): these little probes. And largely because the smaller you you go, um, the more um fragile they are. So they break. So many different approaches have been explored, um, including the likes of stainless steel, microneedles, and it's
3:11
Unidentified speaker (speaker_1): just incredibly hard to manufacture, and the smaller they get. again, the they're at risk for breaking. But silicon is actually harder than titanium and steel at the nanoscale. So we didn't know that. And or industry didn't really know that. And then the semiconductor manufacturing um world really has um been booming. So
3:31
Unidentified speaker (speaker_1): we can leverage the economies of scale from the foundries that uh, you know, make these chips for your your smartphones. So it's at massive scale. So if we were to try this 20 years ago, it would have been cost prohibitive, right? So it's a little bit of right time, right technology. Um, and these microsensors are incredibly
3:51
Unidentified speaker (speaker_1): robust. And that that is the single hardest thing about microsensing is to have a a uh a manufacturable substrate that is robust and enough for you to put chemistries on and that they can actually reside just under your skin without breaking.
4:08
Unidentified speaker (speaker_0): Yeah. And so you you created the this technology and how did you see yourself differentiating beside the technology of reaching out to these diabetic patients? Because when you I'm thinking of CGMs, the clear duopoly right now is DEXCOM and Abbott. Um they definitely have taken most of the type one space. The the the
4:28
Unidentified speaker (speaker_0): new frontier is the type two and those not you needing insulin. So how did you envision this product working for you know that unmet need in the type two space?
4:39
Unidentified speaker (speaker_1): Sure. The type two space not on insulin is the largest population of people with diabetes, representing what up to ninety 95% five percent of people with diabetes. Ninety 90 to ninety 95%. five percent. And to today, date when we look at the tools. available to this this segment, it's largely just been finger sticks and people don't like needles and and and and even if you were
4:59
Unidentified speaker (speaker_1): to do finger sticks, you just can't get enough um information that would um help people see trends and patterns. So if you know our approach was if we could remove some of the um barriers to trying sensency. sensing, in one of them being introducer needles. And if we could
5:19
Unidentified speaker (speaker_1): provide context around um the wearable experience, um, including activity and sleep, and if we can highlight patterns that would be helpful for people that are not on insulin, then that could be the embodiment that could really break through in terms of adoption, right? We have low single digit adoption in the type two space, not on insulin. And and why is
5:39
Unidentified speaker (speaker_1): that? The technologies are fantastic. So and is it the um the introducer needle? Is it um too much information? Is it um alarm and alert fatigue? What is it?
5:51
Unidentified speaker (speaker_0): Yeah. So no, it's just yeah, 'cause it's interesting because like I was saying earlier, I have used this, you know, the c the over the counter CGMs in the past. Seems like a great opportunity. You know, I I don't don't probably need it every day, but you know, for me seeing it once a quarter, you know, just make sure that what I'm eating, you know, seeing the variability in what
6:11
Unidentified speaker (speaker_0): I eat compared to where the shirt glucose levels are and how my exercise is going with that, all seems to be a very compelling case for utilizing that technology. Um but yeah, I mean, but you know, using the the feel was seemed fine. So yeah, I guess it's what else is it to is it just getting that awareness out that this technology is
6:31
Unidentified speaker (speaker_0): there? Um, being able to or is there something else that you guys saw and with your design to be able to get more adherence of the the technology for those who aren't the sickest patients?
6:44
Unidentified speaker (speaker_1): Yes. Simple nudges. Uh and this is actually incredibly complex. Um what do I mean by simple nudges? Well, we we actually in the very um early design phase, we thought about putting some kind of real time feedback on the wearable itself. Could we put an LED light
7:04
Unidentified speaker (speaker_1): to let the user know that they're in target range, right? And then let them know when they're high, let them know when they're falling below target range. And it it's never been done before. because that LED that LED light, the addition of the LED light consumes a large percentage of the power budget.
7:22
Unidentified speaker (UNKNOWN): Oh,
7:23
Unidentified speaker (speaker_0): interesting.
7:23
Unidentified speaker (speaker_1): So we have to sacrifice the duration of the glucose sensing wear time
7:29
Unidentified speaker (speaker_1): in exchange for the power budget that can illuminate um continuously to let you know in real time when you're in target range and when you're high. And we discovered that simple nudges are more powerful than occasional or frequent alerts and alarms. And what I mean by this is somebody with
7:48
Unidentified speaker (speaker_1): type 2 diabetes not on insulin, not frequently seeing a primary care doctor, let's just say, has an A1C of 8% disease progression happening. Well, with somebody with type 2 diabetes with an 8% A1C, they could be in the high range for up to 15 hours a day and not know that.
8:05
Unidentified speaker (speaker_0): Yeah.
8:06
Unidentified speaker (speaker_1): So how could you be high 15 hours a day and not know? Well, if you're not taking finger sticks, you wouldn't know. Yeah. If you're not taking finger sticks when it matters, like after meals, you wouldn't know that your glucose levels have elevated for hours post-meal. And but it's hard to ignore that yellow light when it's flashing and
8:26
Unidentified speaker (speaker_1): blinking. at you for 15 hours. And it does so in a way that's not judgmental, it's not condescending. You can you can snooze it. So we designed a snooze feature. So if you double tap on the wearable, the the LED lights go to sleep.
8:42
Unidentified speaker (speaker_1): So
8:42
Unidentified speaker (UNKNOWN): we
8:43
Unidentified speaker (speaker_1): found that the gentle nudges um are extremely helpful to drive behavior change. above and beyond looking at retrospective historical data and insights. And this comes to the concept of cognitive restructuring, right? So the three things that hap have to happen for teachable
9:03
Unidentified speaker (speaker_1): moments, well, real-time feedback passively when teachable moments arise. And you never know when those teachable moments arise. So having that LED light on unawearable a wearable on your forearm that's within your peripheral vision, that was the big uh aha moment for us. As soon as we had our first working prototype, we knew there was something very special here.
9:23
Unidentified speaker (speaker_0): Yeah.
9:23
Unidentified speaker (speaker_1): Because it's so different than um picking up your phone and responding to an alert an alarm in an app and then looking at your retrospective data.
9:30
Unidentified speaker (speaker_0): I noticed I was picking up my phone a lot more to look at my data from like every five, 10 ten minutes, just to a you know c kind of curiosity. But I guess if you know if I have it there right on my arm with the L E G light, then yeah, I feel like that I don't have to pick up my phone as often and my screen type goes down. It's a win-win. I want to jump back into this cognitive
9:50
Unidentified speaker (speaker_0): restructuring because that sounds like a fan behavior
9:53
Unidentified speaker (UNKNOWN): change.
9:53
Unidentified speaker (speaker_0): Yes. And as a parent with two lovely daughters, you know, sometimes you do want to make sure that their behavior continues that down the right path. So you talked about three steps with this. Um, what are those other couple steps that are the process? You have you, you know, you talked about the passive observations, but
10:13
Unidentified speaker (speaker_0): what are some of those other steps and how does that help the patient? And then for the parents out there, how does that help with the parents leading their kids down the right path?
10:21
Unidentified speaker (speaker_1): So so w
10:22
Unidentified speaker (UNKNOWN): for
10:23
Unidentified speaker (speaker_1): cognitive restructuring, uh, I had mentioned uh you need real time real-time feeling. feedback passively when teachable moments arise. And so it it's incredibly important um because in the absence of live coaching or data dumps or some other forms of alerts and messaging on your phone
10:43
Unidentified speaker (speaker_1): and insights, well, um we learn incredibly fast, um, generally speaking. So um if you were to eat that chocolate cheesecake, right, and uh your sensor goes from blue to yellow, um, without picking up your phone, without your dietitian, without your doctor behind you, without your
11:02
Unidentified speaker (speaker_1): nutritionist, um, you quickly understand that that cheesecake made me spike. And so immediately that cognitive restructuring allows me to remember cheesecake made me spike. And you can actually see, well, what should I do about that? Should I finish this slice of cheesecake? Sure. Um, and
11:22
Unidentified speaker (speaker_1): then if I do finish that slice of cheesecake, I can learn that if I happen to get up and walk 10, 15 minutes, brisk walk, that I come back down into the blue target zone. And so that's another teachable moment that, ah, if I do finish this. incredibly unhealthy dessert, um,
11:42
Unidentified speaker (speaker_1): I can eat these things in moderation because I know what to do. I can stop eating, right, and just eat half of it. Or I could decide to intentionally take a 10, 15 minute brisk walk and get me back down in target range. So these are things that are um incredibly helpful because those are remembered lessons.
12:03
Unidentified speaker (speaker_1): and that cognitive restructuring happens in real time and you don't need AI for that. And so, and by the way, let's just say I forgot to take my walk.
12:15
Unidentified speaker (speaker_1): My yellow light is still on. And it's a gentle reminder that, oh, hey, I'm still yellow. It's been an hour. Maybe I should intentionally get up and and move. So um, so that that restructuring happens. And I think we think that um AI will solve and and AI coaches
12:35
Unidentified speaker (speaker_1): will solve healthier living. And the simplicity of gentle nudges passively hasn't been available until now. So we're seeing some really positive um feedback around this dynamic, around this real-time real feedback. time using color schemas. Um and with cognitive restructuring,
12:55
Unidentified speaker (speaker_1): these lessons learned, if they can stay with a user, then then we get to these occasional wear models. You don't have to wear this full time to learn. Once you learn your patterns, because generally speaking, we probably eat the same types of foods, the twenty 20 same type of meals and foods in what we do on a week to week basis. Um,
13:15
Unidentified speaker (speaker_1): and once you have that foundation and you have those learnings,
13:19
Unidentified speaker (UNKNOWN): they
13:19
Unidentified speaker (speaker_1): stick with you even when you're not wearing the sensor.
13:22
Unidentified speaker (UNKNOWN): Um
13:22
Unidentified speaker (speaker_1): and then, like you, maybe once a quarter, maybe once a year, it's better than nothing.
13:26
Unidentified speaker (speaker_0): Yeah.
13:26
Unidentified speaker (speaker_1): Right.
13:27
Unidentified speaker (UNKNOWN): Yeah,
13:28
Unidentified speaker (speaker_0): very interesting. And then you know, the other question I gotta ask, yeah, and actually my wife was the one who brought it up. I was talking about um
13:35
Unidentified speaker (UNKNOWN): this
13:35
Unidentified speaker (speaker_0): call with you. Um, and she's like, Well, if the sensor's so tiny, how does it stay on the arm? And uh I was explaining the adhesive that goes around it, but but with the sensor that small, it does bring up a good point. How I mean, is it just is it just able to just be able to stick right through and then
13:55
Unidentified speaker (speaker_0): there's no like you know Yeah. potential to t for it to j uh m be a jar as if it gets hit or anything? like that. It seems
14:04
Unidentified speaker (UNKNOWN): like
14:04
Unidentified speaker (speaker_0): it's just just the right size to be able to get into the skin without being too too deep.
14:09
Unidentified speaker (speaker_1): Thanks, Matt. Very um great question. You're the first to ask, actually. I mean we take it for granted. There's actually m a lot of engineering science around that microneedles staying um within your skin. That is perhaps the first misunderstanding around microsensors is that it would back. out or it wouldn't stay in. And so not
14:29
Unidentified speaker (speaker_1): only do we have secure tape around this, but we we architected the microsensors such that they protrude a little bit from the center of the hardware stack so that it's got really good contact with your skin. And then the surrounding tape keeps it in place. And the the great thing about these microsensors is that we designed design them so that each one of
14:49
Unidentified speaker (speaker_1): the probes are individually addressable. So and it's sensing continuously. And so if if the micro sensors happen to be popped out, for example, um let's just say your your your tape came off, then we can actually see your signals go to zero. So we know that they're not when they're not in the
15:09
Unidentified speaker (speaker_1): skin, it's very dramatic and we can see that signal. So generally speaking um the the surface area that we have with the tape in the ratio to where the microsensors are, we have really good um adhesion and the the microneedles and the micro sensors, they they don't move. So um and by the
15:29
Unidentified speaker (speaker_1): way, when you're moving around your skin, yeah the the whole wearable moves with the skin. So it's not like there's a sheer force.
15:36
Unidentified speaker (speaker_0): And so yeah you know, the other thing too I was looking at the um
15:39
Unidentified speaker (speaker_0): FDA summary and I was looking at the accuracy data. I your accuracy is actually in line, it seems. You know, there's apples and oranges because you're there's different ranges that are used for different sensors. But it seems like you're not sacrificing accuracy, um,
15:59
Unidentified speaker (speaker_0): especially in the timing range, but it also looks like with the height hypo, which is an important subgroup of patients because that those are the sickest patients. Is that s is am I making the right observation there? And is that something where, you know, you talk about sensors for general wellness versus sensors for making treatments? Is that a potential
16:19
Unidentified speaker (speaker_0): pathway for this technology to go?
16:23
Unidentified speaker (speaker_1): Yes. We we we see this as um this is perhaps one of the turnkey tools for people not on insulin. Because for people not on insulin, uh
16:34
Unidentified speaker (speaker_1): seeing a particular number, for example, may not mean anything. And especially if you're not dosing insulin. So let's say you eat a banana and you spike to 180 today, and then you eat a banana tomorrow and you spike to 210 tomorrow. It's the same banana. Why did you spike higher you the know, next day? So it it it it so numbers
16:54
Unidentified speaker (speaker_1): um are not the most important thing for people that are not dosing insulin. But as you have disease progression, um and as you move from non-insulin to insulin using, then you would need the wearables and the sensors that provide you with the actual numbers and the the alerts and all the alarms and
17:15
Unidentified speaker (speaker_1): and especially to mitigate severe hypoglycemia. So you'll see different versions of products that we will have with different indications and different claims. So we are working on our insulin dosing claim now. We intend to submit that to the FDA next year.
17:29
Unidentified speaker (speaker_0): Okay.
17:30
Unidentified speaker (speaker_1): And so
17:32
Unidentified speaker (speaker_1): as we start with somebody with type 2 diabetes not an insulin, we'll have products specifically designed. to help drive behavior change. Um and so if we look at why we wear wearables, it doesn't matter if you're a glucose sensor or uh a smart ring or smartwatch, we wear them to give us
17:52
Unidentified speaker (speaker_1): insights so that we can change behavior, right? Make better decisions. And so, and as we progress, then of course, as we get to the insulin dosing claims, you need the alerts and the alarms. And there's a big question. well, would we keep the LED lights? Um, if you have the alerts and alarms on your phone and you can see all the the the trend data and all the the the numbers. Well, the
18:11
Unidentified speaker (speaker_1): answer is yes. Because when you're away from your phone, you're you're running, exercising in the shower, um, and you have a hypoglycemic event, you should still be aware and you should still know about it. And so we could still show the red light, right? And we don't have a pediatric claim now. But for for kids running around in school, and if they have
18:31
Unidentified speaker (speaker_1): severe hypoglycemia, and they're dependent on their phones for the alerts and alarms. But if you can see that red light flashing on the forearm, so everybody around the kid will be able to see that. The teachers, friends,
18:44
Unidentified speaker (speaker_0): family members also care because those kids don't have phones. I mean, we just gave give we just gave our third grader um that gizmo watch because we're trying so hard to prevent them from actually having a phone
18:54
Unidentified speaker (speaker_0): that they don't have access to the phone to be able to get that information. Yeah,
18:57
Unidentified speaker (speaker_1): but back to your question on accuracy, and just I'll I'll jump back to this topic for a second. Um
19:04
Unidentified speaker (speaker_1): there's a trade-off between accuracy and reliability. And so ideally, every sensor in every lot and every batch is exactly the same. And it's a incredibly hard. to do. Same lot,
19:18
Unidentified speaker (speaker_1): you know, being used on the same person week after week, year after year. They should all perform the same. Reliability is incredibly challenging. So we have redundancy built into our sensors. So we have multiple independent channels of glucose information. And that allows us to have more repeatable
19:37
Unidentified speaker (speaker_1): accuracy. And as we mature our manufacturing processes over time and remove some of the outliers in the manufacturing process, then we get to a a really strong accuracy, industry leading accuracy over time. Um so when it comes to reliability, accuracy, and then redundancy and then multi analyte sensing, this is
19:57
Unidentified speaker (speaker_1): where the platform shines. To be able to do all of the above over time with manufacturing maturity is our is our end game. Um, but you have to have a good enough accuracy with really good reliability so that your customers trust the information that you're providing.
20:12
Unidentified speaker (speaker_0): Well, let's jump into that manufacturing component, because that is a big, big
20:18
Unidentified speaker (speaker_0): for the traditional CGMs, a big barrier to entry is being able to build the millions and millions and millions of sensors.
20:28
Unidentified speaker (speaker_0): and being able to have a very
20:31
Unidentified speaker (speaker_0): promising yield of manufacturing them. So what are your steps? Because you know, we we have um we got the approval a year ago. We haven't even talked about the OTC label yet. We'll probably talk about that next. Um, we're kind of jumping around here. But for that, you know, manufacturing.
20:51
Unidentified speaker (speaker_0): capacity to really build scale, what uh what are the investments that are needed? What are the observations you're seeing as you're kind of seeing, you know, the the the spread of good sensors versus the outlier sensors?
21:05
Unidentified speaker (speaker_1): Manufacturing is daunting. Well, largely because there's no precedence for uh an nanosensor with enzyme and membranes. designed for um continuous sensing. So it is daunting. And the the the the platform that our co-founders
21:24
Unidentified speaker (speaker_1): established is really designed for scale to begin with. So on an eight-inch silicon wafer, we could put thousands of chips on an eight-inch silicon wafer. And so we're the only precision membrane deposition technology for many. manufacturing, meaning we literally grow the membranes on the tips of the
21:44
Unidentified speaker (speaker_1): microsensors through an electroplating principle. Very similar to electroplating for jewelry. We use electrodeposition um and we we we highly control how much membrane is grown on each one of the um on each one of the the chips and on each one of the
22:03
Unidentified speaker (speaker_1): microsensors. And so now um every company starts with a manual manufacturing process because you have to optimize your processes and then validate them. And once you have finished optimizing your processes and you've clinically validated them, then that lends to semi-automation
22:22
Unidentified speaker (speaker_1): manufacturing lines. And then of course with um improving your tactile tack times and yields, then it leads to full automation. So it's it's stepwise. And it's not something that you could uh jump immediately into full automation. So for example, if uh and I'm using random numbers numbers here, so don't take this literally, but if you have a process that takes 30 hours,
22:42
Unidentified speaker (speaker_1): well, how do you get that process down to three minutes and then down to thirty 30 seconds and then down to three seconds and then have that fully automated? So that is what we've been spending a tremendous amount of time on over the past year. And so we it will continue to be the focus in the large majority of our use of funds from our fundraising
23:02
Unidentified speaker (speaker_1): efforts is on that manufacturing scale side. And the good news is that the semi automation plans that we have in terms of the the volume of units per line are really extraordinary. So this technology lends itself to scale. It's not as capital intensive as what we've seen in the past, just because of
23:22
Unidentified speaker (speaker_1): the the way in which we make the sensors work. It's orthogonally different. So the chemistries used for the conventional CGM, they don't they don't apply on the microsensing uh technology world. So we use picograms of chemistry. I mean it's just a fraction. I mean what
23:41
Unidentified speaker (speaker_0): is a picogram just for layman like me?
23:44
Unidentified speaker (speaker_1): Yeah, it's just the the amount of um chemistry that we have on the tip of these microsensors, it's really negligible. It's really you you you couldn't see it with a naked eye. Right. Um so um it is precision science and um and we're excited about scaling this. So I think um there hasn't been a
24:04
Unidentified speaker (speaker_1): biosensing platform before. Um now and what I mean by platform is as we move on to the next stack of target biomarkers like lactate, for example, they use the same manufacturing lines. They use the same hardware, same chips, same microsensors, and we just swap out the chemistry. So
24:23
Unidentified speaker (speaker_1): um in and this hasn't been possible in our domain where where we actually have a a manufacturing platform. Um and so doesn't matter what the analyte is, the the processes and the tools that we use are all the same.
24:41
Unidentified speaker (speaker_0): That's fascinating. And
24:42
Unidentified speaker (UNKNOWN): uh
24:43
Unidentified speaker (speaker_0): with that too, though, as you c you build more, you're probably seeing trends and being able to make adjustments for those outliers. Is that how are you addressing those? And is that something that, you know, we talked about going the balance between accuracy and reliability? Is that something where that
25:03
Unidentified speaker (speaker_0): kind of closes and you can almost get both of them at some point down the road?
25:08
Unidentified speaker (speaker_1): We were very intentional about this. This is perhaps our internal superpower, which is the manufacturing process. We can see the health of the microsensors in real time. Because each one of the microsensors are individually addressable. We're monitoring more parameters around the sensor
25:28
Unidentified speaker (speaker_1): and its function in real time as we're manufacturing than any other form of sensors out there today that are commercial. And so these are not, for lack of a better word, dumb filaments that are going through bulk. manufacturing processes. And so because we have so many checkpoints in the manufacturing process, this lends itself to
25:48
Unidentified speaker (speaker_1): AI-driven manufacturing design and protocols, right? So how do we filter out the sensors that don't meet our spec? Well, because we actually could see its performance in real time as it's going through the manufacturing process. you can imagine us being able to screen out those that don't meet our criteria in a more
26:08
Unidentified speaker (speaker_1): automated fashion across an entire batch or or or lot. We also have some bespoke solutions that lends itself to mass sterilization. We have sterilized subcomponents that allow us to do some things at much larger scale than traditionally possible before.
26:27
Unidentified speaker (speaker_1): And the that would be our internal superpower is when we when we have the likes of maturing AI technologies available to us and
26:39
Unidentified speaker (speaker_1): multiple parameters and precision manufacturing available to us. You marry them, and it provides for a really extraordinary manufacturing environment.
26:48
Unidentified speaker (speaker_0): Yeah. And I mean that's it's the thing, is that you're creating the the moat for the technology, but also the moat for the manufacturing process as well. And that's what, you know, helped Dexcom and Abbott with their traditional CGMs.
27:00
Unidentified speaker (speaker_1): Yes.
27:01
Unidentified speaker (speaker_0): Let's talk about then getting back to that over the counter indication because that came out in September. How was those last you know, here we are in November, um, how have those last two months been with kind of the, you know, the acceleration of awareness for this product?
27:18
Unidentified speaker (speaker_1): I couldn't begin to tell you how grateful we are um
27:21
Unidentified speaker (UNKNOWN): with
27:22
Unidentified speaker (speaker_1): for the FDA. Um and
27:25
Unidentified speaker (speaker_1): and we were not expecting the over the counter clearance this quickly. Um there's very little precedence out there for a prescription product to become over the counter almost literally overnight. So we're very grateful. Um, and now this has been exciting for us because it um removing
27:45
Unidentified speaker (speaker_1): the prescription criteria allows us to now open up an e-commerce channel. It allows the DTC programs in collaboration with our pending partners, and it makes a s access easier. Um and so we're extremely excited about. it. So we uh have been working
28:05
Unidentified speaker (speaker_1): on because it came so quickly, um, we have been working on our um packaging for this and our commercial materials for this. So um looking at early next year, we'll have the OTC version available, but it opens up new channels from retail to e-commerce, DTC subscription programs. And so we're incredibly grateful for how
28:25
Unidentified speaker (speaker_1): thoughtful the FDA um has been in in working with us. Um and so this again creates extraordinary access for for more people to to to get.
28:35
Unidentified speaker (speaker_0): It just allows people like me to be able to have access to it, which is you know something that's um I'm very excited to try out um in addition to how I've tried out the Abbott and the DEXCOM versions of them. The DEXCOM and the Abbott versions are currently out of pocket though for those over-the-counter over the counter. uh Um how is that a reimbursement pathway for you? Is it
28:55
Unidentified speaker (speaker_0): something where you're just following Abbott and Dexcom's um pathway there? Or is it a new pathway because it's a new technology?
29:05
Unidentified speaker (speaker_1): This is extremely important. It is um when you look at the next 18 months, aside from manufacturing scale, one of the most important things we can do is generate real world evidence. We do have a new technology category. We do have a new type of sensing, intradermal semiconductor
29:24
Unidentified speaker (speaker_1): biosensors. And we have that real-time feedback that allows it to be fully autonomous when you're wearing it on your forearm and you can see the LED lights. And so the real real-world world evidence will be the foundation for us to seek. uh new pathways for reimbursement. So, um, whether it be Medicare,
29:44
Unidentified speaker (speaker_1): whether it be um opportunities in you know, combining what we're doing with um a disease management solution, obesity care, um, what have you, weight loss programs,
29:56
Unidentified speaker (speaker_1): generating real world evidence over the next 18 months, most important thing that we're doing.
30:00
Unidentified speaker (speaker_0): So so is that something where potentially potenti I'm thinking, you know, clinical data being presented, ADA next year might sound a bit early, but is that something ADA twenty twenty eight, we could see some data published on the real world uh use of the technology?
30:16
Unidentified speaker (speaker_1): Yes, it is our top priority.
30:17
Unidentified speaker (speaker_0): Okay.
30:18
Unidentified speaker (speaker_1): Because the the OTC clearance is fantastic for easier access in reaching more people, but the prescription version is still incredibly important to drive the reimbursement opportunities to create better access for people that need access to the technology. So um what are those lanes? Um, what are those um
30:38
Unidentified speaker (speaker_1): claims that are most important that separates what we're doing from everything else? And what kind of clinical clinical evidence needs um to be done? And there's precedence for this. We we saw um in through a tremendous effort um with JD former JDRF
30:58
Unidentified speaker (speaker_1): and funding the outcome studies that increased access for people with diabetes on insulin for for sensors. Well, um what about the the broader type two population? So we're seeing some really great work coming out of DEXCOM on that front and to applaud their leadership. But um a lot more need needs to be done. And so that is a a very
31:17
Unidentified speaker (speaker_1): expensive proposition and we are committed to it because if we can get expanded reimbursement for type twos, then we can delay disease progression, right? And reduce the cost. I
31:28
Unidentified speaker (UNKNOWN): mean
31:28
Unidentified speaker (speaker_1): if we can find the 20% of people that are consuming 80% of the healthcare costs, we can dramatically lower the cost of care and keep people out of the hospital.
31:36
Unidentified speaker (UNKNOWN): Yeah.
31:36
Unidentified speaker (speaker_0): And that's like that. and if like you know we're talking about the cognitive restructuring. If you can get half of those patients to adjust their lifestyle, then that's a win over the healthcare system.
31:47
Unidentified speaker (UNKNOWN): And
31:47
Unidentified speaker (speaker_1): without a nutritionist, right?
31:48
Unidentified speaker (UNKNOWN): You
31:48
Unidentified speaker (speaker_1): don't have to call your dietitian, right? Um
31:50
Unidentified speaker (speaker_0): you just see the yellow light. Yeah.
31:52
Unidentified speaker (speaker_1): When we eat the donut, we we know shouldn't be eating the donut, right? You don't need a dietitian screaming at you You're saying, Hey, you should be eating this donut. But it's giving me back choice, right? I can still enjoy. what I like, but you know, I can learn to eat half of it. And learning about moderation is one of the biggest things. I mean, instead of a world of no, no, no, no, no, you
32:12
Unidentified speaker (speaker_1): shouldn't do this, you shouldn't do that, well, do that, but
32:15
Unidentified speaker (UNKNOWN): take
32:15
Unidentified speaker (speaker_1): a 15-minute walk. Right. Um, and so just moderation is is key. But inspiration, how how do you those gentle nudges?
32:28
Unidentified speaker (speaker_1): has been really the the the black box of unknowns, right? How do you move people to change behavior? And especially just through very simple cues, right? Everybody can respond to LED lights.
32:39
Unidentified speaker (UNKNOWN): And
32:40
Unidentified speaker (speaker_1): I think we talked about this last time, um, when when we were in the human factors and design phase of the LED lights, we were arguing, I mean, screaming at each other. in terms of what color should be the primary color, right? Should it be a green? You know, should it be purple? And and we landed on a blue. But
33:00
Unidentified speaker (speaker_1): that was incredibly challenging. And I think I shared with you before when we tested green, most people saw the green light as it's okay to eat as much as I want.
33:09
Unidentified speaker (speaker_0): Right?
33:09
Unidentified speaker (UNKNOWN): Because green
33:10
Unidentified speaker (speaker_1): things go,
33:10
Unidentified speaker (UNKNOWN): right?
33:11
Unidentified speaker (speaker_1): So, and that wasn't what we were trying to to accomplish. here. We we wanted, you know, the a color that represented, hey, you're in your target zone and stay in that zone. Yeah.
33:22
Unidentified speaker (speaker_0): We
33:22
Unidentified speaker (speaker_1): didn't want people to see that light and say, Oh, it's time to eat.
33:25
Unidentified speaker (speaker_0): Is it is the yellow for the high for high because you have to have red for the low? And so you you have a red LED there.
33:32
Unidentified speaker (UNKNOWN): Yeah,
33:32
Unidentified speaker (speaker_0): right for that reason.
33:33
Unidentified speaker (speaker_1): We do. We do. Um people responded to yellow a much better passively. Red
33:39
Unidentified speaker (speaker_0): Seems like no.
33:40
Unidentified speaker (UNKNOWN): Yeah,
33:40
Unidentified speaker (speaker_1): red is a lot. Yeah.
33:41
Unidentified speaker (UNKNOWN): And
33:42
Unidentified speaker (speaker_1): you know, do I need to call my doctor right now, right away? Um, and most people um that are not on insulin won't see a lot of hypoglycemia, so you you won't see the red too often. But people with type 2 diabetes could see for hours um high glucose levels.
33:57
Unidentified speaker (UNKNOWN): Yeah.
33:57
Unidentified speaker (speaker_1): So in red was a little bit too intimidating.
33:59
Unidentified speaker (speaker_0): Yeah.
33:59
Unidentified speaker (speaker_1): But it but we had hours and hours. weeks and months on end of of arguments and debate on this and landed on the color schema that we have today. It's
34:07
Unidentified speaker (speaker_0): funny the whole behind the scenes.
34:09
Unidentified speaker (speaker_1): Yeah.
34:10
Unidentified speaker (UNKNOWN): Yeah,
34:10
Unidentified speaker (speaker_0): that's all fascinating. And then, you know, we're talking about the real world data. Will that be will that data be sufficient to then get that dosing um indication? Or is this something where you'll probably even need a an additional clinical trial for that because it needs to be a more rigorous trial?
34:28
Unidentified speaker (speaker_1): Yes. Um it's different. Okay. So real world data is taking our existing products in the target segment of the customers that we'll be um selling to, and then showing that we can actually demonstrate meaningful benefit um in lowering the cost of care, of course. And so for the insulin
34:47
Unidentified speaker (speaker_1): dosing claim, that requires uh an aggressive pay. pivotal trial, no different in design from what we did from the previous emissions. Um in our for biolink shine, our pivotal trial had two-thirds of the people on our pivotal trial had type 1 diabetes. And because you you need you need to demonstrate glucose range, and you can only get
35:07
Unidentified speaker (speaker_1): that range in accuracy and performance in people on insulin. So um, and 90% of the subjects were on insulin. So in 50% of them
35:17
Unidentified speaker (speaker_1): were classified as uh obese. So we covered the whole range of
35:21
Unidentified speaker (speaker_0): the potential
35:22
Unidentified speaker (speaker_1): people with type 2 diabetes.
35:23
Unidentified speaker (UNKNOWN): Um
35:24
Unidentified speaker (speaker_1): for the insulin dosing, we have to include pediatrics. So it is a large pivotal trial that we are kicking off. Um
35:31
Unidentified speaker (UNKNOWN): and
35:32
Unidentified speaker (speaker_1): so we intend to submit to the FDA next year.
35:34
Unidentified speaker (speaker_0): Okay.
35:35
Unidentified speaker (speaker_1): But uh that's also uh one of the important um charters for for us is to expand access to everybody with diabetes, not limited to type two diabetes, but to everybody with diabetes and general health and wellness. Um and so there'll be different tiers of a product with different performance and different claims. But the next one up at bat will
35:54
Unidentified speaker (speaker_1): be for the insulin dosing claim.
35:56
Unidentified speaker (speaker_0): Yeah.
35:57
Unidentified speaker (UNKNOWN): And
35:57
Unidentified speaker (speaker_0): then you know, the other development that you guys are doing is I understand there's a second generation device coming in. out.
36:03
Unidentified speaker (speaker_1): Yes. Or flagship products. Um and the reason I say it's a flagship product, the the first generation was built in the middle of the pandemic, all off-the-shelf components. Um in the second generation is 40% smaller than the first generation. So form factor wise, it's it's a beautiful wearable. Um and so the second generation
36:23
Unidentified speaker (speaker_1): product will also carry our expanded claims. So it'll cover the the RX for type twos, the OTC, and also the insome dosing, all on the same hardware platform. And the type, the, the, the second generation wearable was intended to take us to free cash flow. So it is designed for scale.
36:41
Unidentified speaker (speaker_0): Okay. Interesting. And then because the the the chip is so so small.
36:45
Unidentified speaker (speaker_1): Yes.
36:46
Unidentified speaker (speaker_0): Same chip for the generation.
36:49
Unidentified speaker (UNKNOWN): Yes.
36:49
Unidentified speaker (speaker_0): I I'm assuming at some point down the road you'll be able to have a a second generation chip and a third generation chip, right? Those are just this that's just the natural progression of Moore's law, right? It's
36:59
Unidentified speaker (UNKNOWN): just
36:59
Unidentified speaker (speaker_0): being able to be able to condense more and more into a smaller and smaller chip.
37:03
Unidentified speaker (speaker_1): Yes. Uh it's incredibly thoughtful you were thinking about this. We we actually have some more breakthroughs on the chip itself. We've we've now doubled the density in the same footprint. So we have seven standalone electrodes right now in one array. We've doubled the density to 15 in the same footprint. The
37:22
Unidentified speaker (speaker_1): configurations are literally endless, right? What what is the right number of microsensors we should have? Um, how many should be allocated for redundancy? How many should be allocated for other analytes, multi-analyte combinations? And so it has been incredibly incredible to see the maturity of the chip itself. But
37:42
Unidentified speaker (speaker_1): uh yeah, it's endless combinations we can
37:45
Unidentified speaker (UNKNOWN): do
37:45
Unidentified speaker (speaker_1): there.
37:45
Unidentified speaker (UNKNOWN): Well,
37:45
Unidentified speaker (speaker_0): it just sounds like, and they this is probably how we can close out the episode is you know, we're expanding the chip, we're making it smaller, we're making the form factor smaller. We're here, we are kind of in November, in diabetes awareness month. How do you see this technology playing? out for these diabetic patients over the next
38:05
Unidentified speaker (speaker_0): few years? Is this gonna be, you know, where we think about how crazy it was to even, you know, a small uh the CGMs are small needles, but it's still a needle. Is it gonna be crazy to think that we used to have to have those needles the same way ten years ago? It was crazy to think that we were, you know, we're replacing finger sticks itself.
38:23
Unidentified speaker (speaker_1): I think we should do everything possible to lower the barriers for everyone. everybody to learn about glucose and metabolism. So glucose is the next vital sign. And we just have to make it easier for everybody to pick one up and put it on at least once a year. Right. Everybody should know. And if we could help people understand the relationship with foods they like,
38:43
Unidentified speaker (speaker_1): the medications they're taking, their diet and their exercise, Size, that's half the battle. Right. And then that serves a foundation for improving metabolic health for everybody, whether you have diabetes or not. It is the foundation not only for metabolism, but for longevity. And so, and what are those barriers, right? Um, and if we can
39:03
Unidentified speaker (speaker_1): remove the introducer needle, great. If we can remove an applicator and just have this pressed on like a band-aid, great. If it means um expanding our LED lights into something even more profound, icons.
39:15
Unidentified speaker (speaker_1): right? Trends, words of inspiration on the wearable itself. So there are an infinite number of things that we can do to lower the barrier so that everybody picks one up and uses it. So then that then we would have made it.
39:30
Unidentified speaker (speaker_0): Well, it's actually going back to when my wife was asking me how does it stay on? And When you talked about you can just put it on without an inserter, it's much easier to do it with a microchip than actual uh a needle itself.
39:40
Unidentified speaker (UNKNOWN): It
39:40
Unidentified speaker (speaker_1): is. Yeah.
39:41
Unidentified speaker (speaker_0): It's gonna be fascinating to watch how this develops over the next 18 months, as you
39:45
Unidentified speaker (UNKNOWN): said.
39:45
Unidentified speaker (speaker_0): We'll
39:45
Unidentified speaker (speaker_1): have an OTC one with your name on it.
39:47
Unidentified speaker (speaker_0): Let's go.
39:49
Unidentified speaker (speaker_0): Looking forward to it. Thanks,
39:51
Unidentified speaker (UNKNOWN): man.
39:51
Unidentified speaker (speaker_0): Rich, thanks so much for joining us today. It was a great episode.
39:53
Unidentified speaker (UNKNOWN): Thanks
39:53
Unidentified speaker (speaker_1): for having me back.
39:54
Unidentified speaker (UNKNOWN): Yeah, thanks.
39:55
Unidentified speaker (speaker_0): And uh thank you to our producers, Adidia Samani and Marian Thawele, for all the behind behind-the-scene the scene work. And thank you to our listeners for tuning in today. We hope you join us for future episodes. And if you'd like to stay up to date, you can click the subscribe button on Spotify or your favorite streaming platform. Take
40:10
Unidentified speaker (UNKNOWN): care.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.

More from Vanguards of Healthcare by Bloomberg Intelligence

All insights